Nicolet Bankshares Inc. Purchases 74 Shares of Johnson & Johnson (NYSE:JNJ)

Nicolet Bankshares Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,530 shares of the company’s stock after purchasing an additional 74 shares during the period. Nicolet Bankshares Inc.’s holdings in Johnson & Johnson were worth $1,234,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. IFS Advisors LLC increased its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. Finally, Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $33,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays upped their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Bank of America dropped their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Morgan Stanley lifted their target price on Johnson & Johnson from $163.00 to $164.00 and gave the stock an “equal weight” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $171.67.

Johnson & Johnson Trading Up 2.0 %

Shares of NYSE JNJ opened at $151.62 on Friday. The stock has a market cap of $365.39 billion, a P/E ratio of 22.80, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The firm has a 50 day moving average price of $159.40 and a two-hundred day moving average price of $155.21. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.